Alvotech, the Iceland-based biosimilar company, announced that the first patient has been dosed in the comparative, confirmatory efficacy and safety clinical study (AVT04-GL-301) for AVT04, Alvotech‘s proposed biosimilar to the reference product Stelara®. The objective of the study is to demonstrate therapeutic equivalence between AVT04 and Stelara® in terms of safety, efficacy and immunogenicity in patients with moderate-to-severe chronic plaque psoriasis.
- Read more about Alvotech Initiates Clinical Studies for AVT04, a Proposed Biosimilar to Stelara (Ustekinumab)
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/alvotech-initiates-clinical-studies-for-avt04-a-proposed-biosimilar-to-stelara-ustekinumab
No comments:
Post a Comment